{"version":"1.0","provider_name":"Times South Africa","provider_url":"https:\/\/timessouthafrica.com","author_name":"TSA","author_url":"https:\/\/timessouthafrica.com\/author\/tsa\/","title":"Zenas BioPharma acquiert des droits mondiaux exclusifs sur l\u2019Obexelimab aupr\u00e8s de Xencor - Times South Africa","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"53XWGcHZRs\"><a href=\"https:\/\/timessouthafrica.com\/zenas-biopharma-acquiert-des-droits-mondiaux-exclusifs-sur-lobexelimab-aupres-de-xencor\/\">Zenas BioPharma acquiert des droits mondiaux exclusifs sur l\u2019Obexelimab aupr\u00e8s de Xencor<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/timessouthafrica.com\/zenas-biopharma-acquiert-des-droits-mondiaux-exclusifs-sur-lobexelimab-aupres-de-xencor\/embed\/#?secret=53XWGcHZRs\" width=\"600\" height=\"338\" title=\"&#8220;Zenas BioPharma acquiert des droits mondiaux exclusifs sur l\u2019Obexelimab aupr\u00e8s de Xencor&#8221; &#8212; Times South Africa\" data-secret=\"53XWGcHZRs\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script>\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n<\/script>\n","description":"Xencor re\u00e7oit des droits sur des capitaux propres suppl\u00e9mentaires dans Zenas en tant que paiement initial et est \u00e9ligible \u00e0 un maximum de 480\u00a0millions de dollars en paiements \u00e9chelonn\u00e9s potentiels et redevances sur le chiffre d\u2019affaires net des produits commercialis\u00e9s L\u2019Obexelimab est un nouvel anticorps bisp\u00e9cifique avec un potentiel de premier ordre pour traiter les [\u2026]"}